CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	718.94	401.07	223.52	939.94	1,185	948.81
Short-Term Investments	1,401	1,304	1,603	1,456	521.71	0
Cash & Cash Equivalents	2,120	1,705	1,827	2,396	1,707	948.81
Cash Growth	11.86%	-6.66%	-23.75%	40.35%	79.93%	106.35%
Receivables	0	200	0	0.31	0.14	0.1
Other Current Assets	-0.02	2.8	26.07	21.17	9.3	38.64
Total Current Assets	2,120	1,908	1,853	2,418	1,717	987.55
Property, Plant & Equipment	298.51	305.94	320.56	312.04	93.03	72.83
Long-Term Investments	0	1.97	53.13	0	0	0
Goodwill and Intangibles	0	0.02	0.07	0.13	0.18	0.24
Other Long-Term Assets	20.88	13.57	16.28	22.2	18.14	6.14
Total Long-Term Assets	319.39	321.49	390.03	334.36	111.35	79.21
Total Assets	2,439	2,230	2,243	2,752	1,828	1,067
Accounts Payable	16.46	38.15	27.43	14.82	9.09	5.94
Deferred Revenue	17.61	18.12	12.32	13.33	14.12	12.74
Current Debt	15.99	15.63	15.84	12.16	11.36	8.49
Other Current Liabilities	68.92	36.9	65.51	79.58	59.69	29.94
Total Current Liabilities	118.99	108.79	121.11	119.88	94.26	57.11
Long-Term Debt	218.94	223.01	228.18	212.87	50.07	44.05
Other Long-Term Liabilities	17.16	14.97	18.29	19.66	19.41	26.17
Total Long-Term Liabilities	236.09	237.98	246.47	232.53	69.47	70.22
Total Liabilities	355.08	346.77	367.58	352.42	163.73	127.33
Total Debt	234.93	238.63	244.02	225.03	61.43	52.54
Debt Growth	-2.22%	-2.21%	8.44%	266.33%	16.92%	-
Retained Earnings	-1,116.29	-999.7	-846.09	-195.92	-573.58	-224.71
Comprehensive Income	-1.55	1.91	-15.65	-5.07	-0.08	0.01
Shareholders' Equity	2,084	1,883	1,875	2,399	1,664	939.43
Net Cash / Debt	1,885	1,467	1,583	2,171	1,646	896.27
Net Cash / Debt Growth	13.91%	-7.35%	-27.09%	31.92%	83.62%	94.92%
Net Cash Per Share	23.04	18.51	20.36	27.00	24.95	15.74
Working Capital	2,001	1,799	1,732	2,298	1,622	930.44
Book Value Per Share	25.48	23.77	24.12	31.59	25.23	17.27

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).